213 related articles for article (PubMed ID: 33575085)
1. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.
Bauer K; Berghoff AS; Preusser M; Heller G; Zielinski CC; Valent P; Grunt TW
Am J Cancer Res; 2021; 11(2):530-545. PubMed ID: 33575085
[TBL] [Abstract][Full Text] [Related]
2. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
Bauer K; Hauswirth A; Gleixner KV; Greiner G; Thaler J; Bettelheim P; Filik Y; Koller E; Hoermann G; Staber PB; Sperr WR; Keil F; Valent P
Am J Hematol; 2024 Jun; ():. PubMed ID: 38822666
[TBL] [Abstract][Full Text] [Related]
3. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.
Bauer K; Berger D; Zielinski CC; Valent P; Grunt TW
Oncotarget; 2018 May; 9(41):26491-26506. PubMed ID: 29899872
[TBL] [Abstract][Full Text] [Related]
4. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
5. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
6. BRD4: New hope in the battle against glioblastoma.
Duan W; Yu M; Chen J
Pharmacol Res; 2023 May; 191():106767. PubMed ID: 37061146
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
8. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of BRD4 degraders.
Ding M; Shao Y; Sun D; Meng S; Zang Y; Zhou Y; Li J; Lu W; Zhu S
Bioorg Med Chem; 2023 Jan; 78():117134. PubMed ID: 36563515
[TBL] [Abstract][Full Text] [Related]
11. The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.
Zhu X; Liu W; Tang X; Chen Y; Ge X; Ke Q; Liang X; Gan Y; Zheng Y; Zou M; Deng M; Liu Y; Li DW; Gong L
J Neuroinflammation; 2023 May; 20(1):119. PubMed ID: 37217935
[TBL] [Abstract][Full Text] [Related]
12. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
15. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4.
Calder J; Nagelberg A; Luu J; Lu D; Lockwood WW
Oncogenesis; 2021 Mar; 10(3):27. PubMed ID: 33712563
[TBL] [Abstract][Full Text] [Related]
16. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
18. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
Front Oncol; 2021; 11():753119. PubMed ID: 34733788
[TBL] [Abstract][Full Text] [Related]
19. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
20. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
